

Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal)

Technology appraisal guidance

Published: 5 June 2024

www.nice.org.uk/guidance/ta980

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of nivolumab for the adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over. This is because Bristol-Myers Squibb (BMS) has confirmed that it does not intend to make an evidence submission for the appraisal. BMS considers that the technology will not be launched in the UK for treating this indication.

Information

If NHS organisations wish to consider nivolumab for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-6155-9